

| TITULO | REVISTA | FI | Q | DOI | UT (Unique WOS ID) | Pubmed Id |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|--------|----|-------------------------------|---------------------|-----------|
| Are there differences by sex in lung cancer characteristics at diagnosis? - a nationwide study | TRANSLATIONAL LUNG CANCER RESEARCH | 4,726 | Q2 | 10.21037/tlcr-21-559 | WOS:000718295000005 | 34858780 |
| Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial | CLINICAL AND TRANSLATIONAL MEDICINE | 8,554 | D1 | 10.1002/ctm2.491 | WOS:000678754500016 | 34323406 |
| Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial | JOURNAL OF THORACIC ONCOLOGY | 20,121 | D1 | 10.1016/j.jtho.2021.07.035 | WOS:000721176100017 | 34537440 |
| Chemotherapy de-escalation using an F-18-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial | LANCET ONCOLOGY | 18,998 | D1 | 10.1016/S1470-2045(21)00122-4 | WOS:000657432100051 | 34019819 |
| Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial | JOURNAL FOR IMMUNOTHERAPY OF CANCER | 12,469 | D1 | 10.1136/jitc-2021-002804 | WOS:000691008700002 | 34446577 |
| Do Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method | HEALTHCARE | 3,160 | Q2 | 10.3390/healthcare9060665 | WOS:000666704100001 | 34205026 |
| DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy | FUTURE ONCOLOGY | 3,674 | Q3 | 10.2217/fon-2021-0952 | WOS:000718411900001 | 34775804 |
| Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain | BMC CANCER | 4,638 | Q2 | 10.1186/s12885-020-07758-5 | WOS:000610556700004 | 33446148 |
| Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group | JOURNAL OF GERIATRIC ONCOLOGY | 3,929 | Q3 | 10.1016/j.jgo.2020.11.010 | WOS:000634391900011 | 33357975 |
| Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry | PLOS ONE | 3,752 | Q2 | 10.1371/journal.pone.0251761 | WOS:000664638500016 | 34077442 |
| Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study | HEALTH AND QUALITY OF LIFE OUTCOMES | 3,077 | Q2 | 10.1186/s12955-021-01876-9 | WOS:000708471700001 | 34663356 |
| External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 5,485 | Q2 | 10.1177/17588359211019672 | WOS:000688566300001 | 34211587 |
| FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and >= 3 circulating tumour cells: the randomised phase III VISNu-1 trial | ESMO OPEN | 6,883 | Q1 | 10.1136/esmoopen-2020-000944 | WOS:000591346900001 | 33148620 |
| Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM) | ESMO OPEN | 6,883 | Q1 | 10.1016/j.esmoop.2021.100048 | WOS:000644690600003 | 33556897 |
| Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L) | LUNG CANCER | 6,081 | Q1 | 10.1016/j.lungcan.2021.03.005 | WOS:000644431300010 | |
| Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry | GASTRIC CANCER | 7,701 | Q1 | 10.1007/s10120-021-01169-6 | WOS:000624364300001 | 33651195 |

| | | | | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|--------|----|-------------------------------|---------------------|----------|
| Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer? | VIRCHOWS ARCHIV | 4,535 | Q2 | 10.1007/s00428-021-03104-7 | WOS:000660790300001 | 33934230 |
| Lung cancer patients with COVID-19 in Spain: GRAVID study | LUNG CANCER | 6,081 | Q1 | 10.1016/j.lungcan.2021.05.014 | WOS:000658344500015 | 34016490 |
| LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology | CANCER MEDICINE | 4,711 | Q2 | 10.1002/cam4.4135 | WOS:000676107800001 | 34296539 |
| NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment | MOLECULAR ONCOLOGY | 7,449 | Q1 | 10.1002/1878-0261.13033 | WOS:000663081600001 | 34058070 |
| Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study | EUROPEAN JOURNAL OF CANCER | 10,002 | Q1 | 10.1016/j.ejca.2021.07.004 | WOS:000703177400007 | 34425406 |
| Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group | BMC CANCER | 4,638 | Q2 | 10.1186/s12885-021-07922-5 | WOS:000626587700004 | 33676426 |
| Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL | ANNALS OF ONCOLOGY | 51,769 | D1 | 10.1016/j.annonc.2020.12.013 | WOS:000629502100010 | 33385521 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study | LANCET ONCOLOGY | 18,998 | D1 | 10.1016/S1470-2045(20)30642-2 | WOS:000615917800028 | 33460574 |
| PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis | JOURNAL OF CLINICAL MEDICINE | 4,964 | Q2 | 10.3390/jcm10194583 | WOS:000757366800022 | 34640601 |
| Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial | EUROPEAN JOURNAL OF CANCER | 10,002 | Q1 | 10.1016/j.ejca.2021.02.028 | WOS:000644993500005 | 33794440 |
| Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data | SCIENTIFIC REPORTS | 4,996 | Q2 | 10.1038/s41598-021-93732-5 | WOS:000677494000007 | 34253805 |
| Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy | CLINICAL CANCER RESEARCH | 13,801 | D1 | 10.1158/1078-0432.CCR-21-1200 | WOS:000714656500019 | 34376534 |
| Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data | BMC CANCER | 4,638 | Q2 | 10.1186/s12885-021-08713-8 | WOS:000692398700002 | 34465283 |
| Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches | FARMACIA HOSPITALARIA | | | 10.7399/fh.11762 | WOS:000734840400004 | |
| Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study | ESMO OPEN | 6,883 | Q1 | 10.1016/j.esmoop.2021.100090 | WOS:000644690600036 | 33740735 |

| | | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------|----|-----------------------------|---------------------|----------|
| SEOM clinical guideline in ovarian cancer (2020) | CLINICAL & TRANSLATIONAL ONCOLOGY | 3,340 | Q3 | 10.1007/s12094-020-02545-x | WOS:000613035800002 | 33515422 |
| SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) | CLINICAL & TRANSLATIONAL ONCOLOGY | 3,340 | Q3 | 10.1007/s12094-020-02532-2 | WOS:000614690500001 | 33538989 |
| Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study | TRANSLATIONAL LUNG CANCER RESEARCH | 4,726 | Q2 | 10.21037/tlcr-21-504 | WOS:000730815700001 | 35242627 |
| Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial | JAMA ONCOLOGY | 33,006 | D1 | 10.1001/jamaoncol.2021.4761 | WOS:000714599500001 | 34647988 |
| Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials | CANCER MEDICINE | 4,711 | Q2 | 10.1002/cam4.4089 | WOS:000686455000001 | 34405547 |